Silicon as a Bioisostere for Carbon in Drug Design

In the pursuit of novel therapeutic agents, medicinal chemists often employ the concept of bioisosterism – the replacement of one atom or group in a molecule with another atom or group having similar physical or chemical properties. Silicon, due to its chemical similarity to carbon, has emerged as a fascinating bioisostere in drug design.

Silicon in Medicinal Chemistry

Silicon, located directly below carbon in the periodic table, shares many of its chemical properties but also offers distinct advantages as a bioisostere:

  1. Larger Atomic Radius: Silicon has a larger atomic radius than carbon, which can influence molecular shape and steric interactions.
  2. Increased Lipophilicity: Compounds with silicon may exhibit increased lipophilicity compared to their carbon analogs, potentially enhancing cell membrane permeability. See this case study for an illustration of this effect.
  3. Metabolic Stability: Silicon-containing compounds often show enhanced metabolic stability, which can be beneficial in extending the drug's effective half-life in the body.

Looking at a 3D model makes these differences obvious: the Si–C bonds in silafluofen are substantially longer than C–C bonds, which alters the shape of the molecule and the dihedral preferences of other bonds.

Applications of Silicon Bioisosteres

Silicon in Drug Candidates

Silicon has been used to replace carbon in various functional groups like alcohols, ketones, and amides. These modifications have resulted in compounds with altered pharmacokinetic and pharmacodynamic profiles, sometimes leading to improved therapeutic properties.

Case Studies

Several studies have demonstrated the potential of silicon bioisosteres. For instance, replacing a carbon atom with silicon in certain compounds has resulted in increased potency, selectivity, and metabolic stability. Here's some case studies:

There are lots more papers out there: see for instance this recent review.

Challenges in Silicon Bioisosterism

Despite its potential, the use of silicon as a bioisostere presents challenges:

  1. Synthetic Difficulty: Introducing silicon into organic molecules can be more challenging than traditional carbon-based synthesis. Nevertheless, more and more Si-containing building blocks are now available: see, for instance, this list from Enamine.
  2. Predicting Biological Effects: The effects of silicon substitution on biological systems are not always predictable, necessitating extensive testing.

Computational Chemistry and Silicon Bioisosteres

Advanced computational tools are crucial in predicting the effects of silicon substitution in drug molecules. Quantum chemistry, accessible through platforms like Rowan, can provide insights into the electronic structure, reactivity, and conformational changes resulting from silicon substitution. This predictive power is invaluable in the early stages of drug design. Computational studies also aid in understanding how silicon substitution impacts a drug's metabolism, helping to predict its pharmacokinetic behavior.

Conclusion

The use of silicon as a bioisostere for carbon in drug design is an area of growing interest. While challenges remain, the potential for developing novel therapeutics with improved properties is significant. Continued research, aided by computational chemistry tools like those offered by Rowan, is essential for advancing our understanding and application of silicon bioisosteres in medicinal chemistry.

For researchers interested in exploring the innovative realm of silicon bioisosteres, Rowan provides the computational platform necessary for such advanced studies. Begin your journey in pioneering drug design by creating an account at labs.rowansci.com/create-account.

Banner background image

Start running calculations in minutes!

Our platform lets you submit, view, analyze, and share calculations using cutting-edge methods trusted by hundreds of leading scientists. We give every new user 500 free credits to start, plus more every week. Making an account and running your first calculation takes only seconds: start using Rowan today!

Start computing →

What to read next

Improving Rowan's Performance on the OpenBind EV-A71 Release

Improving Rowan's Performance on the OpenBind EV-A71 Release

How we recovered useful RBFE accuracy on a challenging real-world dataset.
May 20, 2026 · Corin Wagen
New Protein Visualizations

New Protein Visualizations

distilling insight from complexity; two-dimensional protein–ligand interaction diagrams; protein blob surfaces; space-filling molecule representations
May 19, 2026 · Ari Wagen
Notes on Rowan Engineering; Or How to Vibe-Refactor a Codebase

Notes on Rowan Engineering; Or How to Vibe-Refactor a Codebase

stuck in Rowan's dependency slough of despond; fleeing the complexity of microservices & partial refactors; multiplying packages to reduce complexity; using agents to vibe-refactor our whole codebase
May 13, 2026 · Jonathon Vandezande
Testing Rowan on the OpenBind EV-A71 Release

Testing Rowan on the OpenBind EV-A71 Release

How Rowan's analogue-docking and RBFE workflows fare on this dataset.
May 6, 2026 · Corin Wagen
Benchmarking Membrane-Permeability Predictors

Benchmarking Membrane-Permeability Predictors

Testing GNN-MTL and PyPermm on datasets of small molecules, macrocycles, and PROTACs
Apr 28, 2026 · Ari Wagen
Smarter Analogue Docking, Pocket Detection, and g-xTB Analytical Gradients

Smarter Analogue Docking, Pocket Detection, and g-xTB Analytical Gradients

more robust MCS detection; conformer sampling with torsional Monte Carlo; better alignment and RBFE results; a new pocket-detection workflow; analytical gradients now available for g-xTB
Apr 23, 2026 · Zachary Fried, Corin Wagen, Ari Wagen, and Jonathon Vandezande
g-xTB pKa and Website Redesign

g-xTB pKa and Website Redesign

the flaws with Rowan's AIMNet2-based pKa method; our new g-xTB-based approach; benchmarking and availability; a logo and new website for Rowan
Apr 15, 2026 · Corin Wagen and Ari Wagen
Easter Updates to Rowan

Easter Updates to Rowan

webhooks, draft workflows, and usage estimates for Rowan's Python API; tautomers in non-aqueous solvents; COSMO-based descriptors; overage-based billing; an FEP speed test; welcome Zach
Apr 9, 2026 · Eli Mann, Ari Wagen, Spencer Schneider, Jonathon Vandezande, and Corin Wagen
How Fast Can FEP Run?

How Fast Can FEP Run?

Pushing the speed limit for RBFE calculations run through TMD.
Apr 8, 2026 · Corin Wagen
Improving Rowan's API

Improving Rowan's API

API as a coequal interface to Rowan's product; what we're changing in v3.0.0 of rowan-python; typed outputs; new workflow API; more agent-friendly features; acknowledging our early partners here
Mar 19, 2026 · Eli Mann, Corin Wagen, Jonathon Vandezande, and Spencer Schneider